Cambridge, Mass. – August 15, 2017 – Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, today announced that Teresa (Terry) Regan has joined the company as its first full-time vice president of human resources.
Ms. Regan has over twenty years of human resources experience in the biotechnology space. As the first head of human resources at Cubist Pharmaceuticals, she was instrumental in supporting the company through its research, development and commercialization lifecycle. Following Cubist, Ms. Regan joined Compound Therapeutics where she oversaw all human resources functions, including change management, as the company transitioned to Adnexus Therapeutics. Following this, Ms. Regan moved to Tolerx as vice president of human resources where she fostered an extraordinary corporate culture and saw the company through a period of rapid growth.
For the past five years Ms. Regan has consulted to many prominent biotechnology companies, providing leadership, strategic guidance and coaching for senior executives. Ms. Regan holds a Bachelor of Arts in Psychology from Clark University and Master of Science in Human Resources Management from Suffolk University.
“We are very excited to have Terry join our senior leadership team,” said Hugh O’Dowd, chief executive officer at Neon Therapeutics. “As our first full-time head of human resources, Terry will oversee the continued growth of the company, and we look forward to leveraging her experience and wisdom to ensure that Neon Therapeutics will remain true to our core values and culture.”
“Neon Therapeutics is singularly focused on curing cancer, and already has an amazing team in place,” said Ms. Regan. “I am so excited to be part of this truly exceptional company and assist in its growth and development.”
About Neon Therapeutics
Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine allows Neon to develop multiple treatment modalities, including next-generation vaccines and T cell therapies targeting both personal and select neoantigens. Neon’s lead program is a personal neoantigen vaccine that builds upon years of research and development at the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute, and is in multiple clinical trials. For more information, please visit www.neontherapeutics.com.
Ten Bridge Communications, Inc.